Blue Cross covering Egrifta
From Blue Cross:
Changes to our self-injectable drugs policy
Effective January 1, 2011, two changes will be made
to Medical Policy #08.00.78: Self-Injectable Drugs, as
detailed below.
Adding tesamorelin (Egrifta)
In anticipation of approval from the U.S. Food and Drug
Administration (FDA), tesamorelin (Egrifta) will be added
to the Self-Injectable Drugs policy. Tesamorelin (Egrifta)
will only be made available under the pharmacy benefit;
it will not be available under the medical benefit. Please
note that tesamorelin (Egrifta) is not eligible for coverage
until the drug receives FDA approval.
https://www.ibx.com/pdfs/providers/communications/update/2010/update_dec10_ibc.pdf